Brain Regeneration Technology Stock Soars 283% on FDA Approval News

Brain Regeneration Technology, a biotech company listed on the U.S. stock market, experienced a staggering 283% surge in its stock price overnight, closing at a record high of 60 dollars per share. This dramatic increase catapulted the company's market capitalization to 29.669 billion dollars, marking an over 50-fold rise in its stock value for the year. This performance has positioned Brain Regeneration Technology as one of the standout stocks in the U.S. market for 2025.

The surge in Brain Regeneration Technology's stock price has had a significant impact on related sectors, particularly in the brain-computer interface (BCI) technology space. This ripple effect was evident in both the Hong Kong and mainland China stock markets, where BCI concept stocks saw substantial gains. For instance, Nanjing Panda Electronics in Hong Kong opened with a 43.71% increase, while Weichuang Brain Science saw a 25.80% rise. In mainland China, several companies involved in BCI technology, such as Aipeng Medical, Chuanxin Medical, and Beiyi Brain Science, experienced significant gains, with some stocks hitting their daily limit.

Brain Regeneration Technology, despite having only 12 employees and a decade of operation, has captured market attention with its focus on using traditional Chinese medicine to treat neurological disorders. However, the company has reported zero revenue and accumulated losses exceeding 10 million dollars from 2021 to 2024. The catalyst for its stock surge was the announcement on May 9 that its "next-generation neural control chip" had passed FDA clinical trial approval and that it was collaborating with the Mayo Clinic for Parkinson's disease treatment research. Despite media investigations revealing no official confirmation from the FDA or the Mayo Clinic, market enthusiasm remained undeterred, further fueled by the company's 38-for-1 stock split on June 13, which increased the number of shares in circulation and attracted a surge of retail investors.

In mainland China, companies deeply involved in BCI technology, such as Hangzhou Boling Brain Machine, which has initiated clinical trials for 50 patients and is benchmarking its technology against Neuralink, and Beiyi Brain Science, which has developed the "Beiyi No. 1" wireless implant system with leading international precision, saw their stocks surge to their daily limits. In Hong Kong, Nanjing Panda Electronics' project on integrating key technologies for a multi-modal human-computer interaction system based on BCI technology has entered the pre-clinical testing phase, aiming to develop intelligent interactive display terminals. Weichuang Brain Science benefited from the success of China's first invasive BCI clinical trial, driving its stock to a near one-year high.

The boom in BCI concept stocks is driven by multiple factors within the industry. Neuralink, founded by Elon Musk, recently completed a 650 million dollars Series E funding round, valuing the company at 9 billion dollars. Additionally, China's first invasive BCI clinical trial was announced successful on June 16, marking a significant milestone in the technology's practical application. Policies in major cities like Beijing and Shanghai have also been supportive, with action plans outlining goals to achieve full clinical application of BCI products by 2030 and to cultivate 3-5 global leading enterprises in this field. The National Medical Insurance Administration has also established specific pricing for BCI technology services, further accelerating its commercialization.

The global BCI market is projected to reach 29.3 billion dollars by 2025, with China's market size expected to surpass 380 million dollars. As clinical trials progress and medical applications become more commercialized, the entire industry chain, from upstream sensor and chip suppliers to downstream medical rehabilitation and smart home applications, is poised for growth. The development of BCI technology, transitioning from laboratory research to market application, shows promising prospects, particularly in the medical field, where its potential market size is estimated to reach 400 billion to 1.45 trillion dollars by 2030-2040. With ongoing research and development, and the establishment of ethical guidelines, BCI technology is expected to bring significant advancements to the field of medicine and technology.